Cyramza 500mg Injection

About

Cyramza 500mg Injection, containing ramucirumab, is a human IgG1 monoclonal antibody that specifically targets and binds to the vascular endothelial growth factor receptor 2 (VEGFR-2). By blocking the binding of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D) to VEGFR-2, ramucirumab effectively inhibits receptor activation and subsequent downstream signaling pathways. This action leads to the inhibition of angiogenesis, the formation of new blood vessels that supply tumors with essential nutrients and oxygen, thereby impeding tumor growth and metastasis. It is a targeted therapy used in the treatment of various advanced solid tumors, often in combination with other chemotherapeutic agents, particularly after prior systemic therapy has failed.

The therapeutic utility of Cyramza 500mg Injection lies in its ability to disrupt the tumor's blood supply, which is crucial for its survival and proliferation. It is indicated for conditions such as advanced gastric or gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), and hepatocellular carcinoma (HCC). Due to its mechanism of action, patients receiving ramucirumab require careful monitoring for potential adverse effects, including hypertension, proteinuria, and hemorrhagic events.

Uses

• Advanced gastric or gastroesophageal junction adenocarcinoma
• Metastatic non-small cell lung cancer (NSCLC)
• Metastatic colorectal cancer (mCRC)
• Hepatocellular carcinoma (HCC)

Directions For Use

Administered intravenously by a healthcare professional. The dosage and infusion schedule depend on the specific cancer type and whether it is used as monotherapy or in combination.

Benefits

• Improves overall survival in advanced cancers.
• Targets a key pathway in tumor angiogenesis.
• Can be used as monotherapy or in combination.
• Offers a treatment option for refractory cancers.
• Well-characterized safety profile for its class.
• Provides disease control in advanced settings.

Side Effects

• Hypertension
• Proteinuria
• Hemorrhage (including gastrointestinal)
• Thromboembolic events
• Gastrointestinal perforation
• Fatigue
• Headache
• Diarrhea
• Abdominal pain
• Neutropenia
• Infusion-related reactions
• Arterial thrombotic events

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but moderation is generally advised during cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm based on its mechanism of action. Use effective contraception.
• Breastfeeding - Not recommended during breastfeeding due to the potential for serious adverse reactions in the breastfed infant.
• Liver - Use with caution in patients with severe liver impairment; close monitoring for adverse effects is recommended.
• Kidney - Use with caution in patients with severe renal impairment; monitoring for proteinuria and other renal adverse events is important.
• Lung - No specific contraindication, but monitor for pulmonary hemorrhage, especially in lung cancer patients.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.